A new daily MS pill is seeking regulatory approval in 2026

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

Advanced drugs are closing in on cancer's deadliest mutations

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

The FDA rejected MDMA-assisted therapy for PTSD in 2024, calling for more research

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

The US FDA considered mitochondrial replacement therapy during 2014 hearings

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.

CAR-T is showing promise for treating lupus—previously thought to be incurable

A small number of lupus patients have remained in complete remission for years after undergoing an experimental CAR-T cell therapy that seems to eliminate enough B cells to fuel a "deep reset" of the immune system. CAR-T therapy is also being used experimentally to treat MS, myositis, and other autoimmune disorders. (Some users may experience a paywall.)

A man with organ failure used AI to speed discovery of his miracle drug

David Fajgenbaum had a few months to live after a diagnosis with a rare form of Castleman's disease. By studying his blood, medical records, and broader literature, he was able to identify the cause of his condition and a treatment. He's been in total relapse for ten years.

The first CRISPR-approved treatment was for sickle cell anemia in 2023

Victoria Gray was the first patient to receive a CRISPR-based therapy, which eliminated her symptoms and restored her health. The therapy's initial cost of $2.2M has kept it out of reach of many patients.

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

The US FDA issued a 2025 warning about BPC-157 and other popular peptides

BPC-157, which mimics a naturally occurring gut peptide involved in soft tissue repair, has been marketed for various regenerative properties. But the FDA warned in July 2025 that it doesn't have enough data to assess its safety in humans and that such products may also pose risks related to contamination.

A snapshot of progress in cancer treatments

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

The new antibiotic killing drug-resistant bacteria

A new class of antibiotics had not been discovered in more than 50 years—until late 2023, when MIT researchers announced a new antibiotic called Zosurabalpin. In animal testing, Zosurabalpin was able to treat at least one type of superbug. While the drug still needs to go through clinical trials, it is a significant advance at a time when new antibiotics are in great demand.

More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010

The complexity of Alzheimer's disease, coupled with decades of underfunded research efforts, has left patients with little in the way of effective treatments. In recent years, scientists have synthesized several drugs that studies show can slow the progression of Alzheimer's—though the disease itself remains incurable.

MS Drugs reduce inflammation, helping reduce relapses and slow disease progression

Disease-Modifying Drugs calm the body's inflammatory response to help stave off relapses—when new or existing MS symptoms show up for a day or longer. Avoiding smoking, exercising, reducing stress via mindfulness, checking for vitamin D deficiencies, drinking more water and eating well, all can slow disease progression. [The jury's still out on if HRT around the time of menopause may reduce dementia risk](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00122-9/fulltext) Estrogen can reduce inflammation and support neural growth in the brain, and some research has suggested that beginning hormone replacement therapy around menopause—versus later in life—reduces Alzheimer's disease risk. Still, a recent systematic review concluded that taking HRT didn't affect dementia risk, regardless of when women started taking it, so the science remains unsettled.

FDA removed its cardiovascular risk warning on testosterone products in 2025

The change came a decade after the FDA added the label. Recent work, including a gold-standard randomized trial, found that men receiving the products had similar cardiovascular risk levels as men taking placebo products. Testosterone, however, may hold other health risks, including infertility.

There are more than 1,400 listed clinical trials for macular degeneration

The US database of clinical trials listed more than 1,400 macular degeneration trials in early 2026. That doesn't mean every trial is recruiting, but it does indicate there is significant interest in this medical condition.

FDA approved the first ever peanut allergy treatment in January 2020

This new medication, called Palforzia, is designed to stave off severe reactions from accidental peanut exposures with a daily dose that is increased over time under an allergist’s supervision. It’s not a treatment that should be administered during an allergic reaction, however. Epinephrine, usually administered via injection, remains the intervention for severe reactions.

Two Lyme disease vaccines were in development in 2026

As of early 2026, there was no vaccine for Lyme disease available. One candidate vaccine, VLA15, was in later-stage clinical trials. Another designed to provide seasonal protection was licensed to a pharmaceutical company in 2025, and was planned for human clinical trials.

Fentanyl is better at crossing the blood-brain barrier than other opioids

Among opioids, fentanyl is uniquely adept at crossing the blood-brain barrier—the brain's security fence against harmful substances. This enables a lightning-fast high. It ends just as quickly, sometimes within minutes (where a heroin high lasts hours), and still results in the same withdrawal symptoms.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

How semaglutides are both better and worse than we know

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.

Pharmaceutical companies can use ChatGPT to improve drug development

Moderna has incorporated the tool into its workflows to accelerate analysis and identify optimal drug dosage from clinical data. The company's legal team also uses a custom GPT—Contract Companion—to break down and summarize contracts quickly.

Telehealth demand for GLP-1s for weight loss is booming as consumers seek easier access.

MS can damage the brain up to 7 years before symptoms appear

Recent research scouring blood samples from 134 people with MS, both before and after their diagnosis, found that about seven years before these patients were diagnosed, there was a spike in a protein called myelin oligodendrocyte glycoprotein—indicating disease-associated damage to the protective myelin around nerve fibers.

A 49-year-old American died at an ibogaine clinic in Mexico, underscoring its risks

The man had sought out the drug to help him overcome his substance abuse disorder. Though anecdotal reports indicate potential promise, there's been no large-scale clinical trials on ibogaine's safety and efficacy. The plant is derived from a root bark named iboga and has been used for centuries by indigenous communities in Gabon, but first entered scientific consciousness in 1901 after its alkaloid was isolated from Iboga.

Biotech ETFs allow investors to gain exposure to multiple promising companies in the industry

Biotech ETFs offer a diversified alternative to purchasing an individual biotech stock and gambling on whether an individual company’s clinical trial yields the next blockbuster cancer treatment or an absolute flop. This list of the top biotech ETFs in 2025 can help you learn more about them.

Hikma v. Amarin is a case the Supreme Court is hearing in 2026 that could impact how much you ultimately pay for prescription drugs

The case explores the liability of a generic drug maker for patent infringement. Hikma Pharmaceuticals launched a generic for Amarin Pharma's Vascepa (a fish oil drug), carving out a still-patented use and instead explicitly selling its product for another unprotected use. But Hikma was sued for its marketing materials that still alluded to the patented indication without outright referencing it.

An Ebola vaccine was developed during the 2018 west African Ebola outbreak, but the 2026 Ebola outbreak is with a different species of the virus, not the one that the vaccine is approved to treat.

Read a deep dive on the 'all-purpose healing' peptide BPC-157.

The hormonal disorder PCOS was renamed PMOS in 2026, a move designed to improve care and research by shifting the focus to the hormonal causes of this condition that affects 1 in 8 women.

11 people died from firework injuries in the US in 2024.

Listen to an in-depth conversation on the links between Parkinson's disease and herbicide exposure and the challenging pace of scientific investigation.

The first line of 'immortal' human cells, which can divide indefinitely and are used in scientific research, was nonconsensually taken from a Black woman.

As of 2025, the most cited papers in science include a review of graphene, methods to improve image recognition, streamlining electron density calculations, and optimizing protein studies.

An investigation suggests a Scottish island became awash in forever chemicals via seafoam and seaspray—raising questions about what that means for the safety of other coastal areas.

Apeirophobia is an overwhelming fear of living forever, perhaps stemming from the brain's inability to conceptualize an infinite life.

Astronauts have repaired genetic damage in space using CRISPR—a molecular tool that can make precise changes to DNA and is used in single-celled organisms to attack invasive viruses.

Bone marrow (soft tissue found inside certain bones) generates roughly 500 billion new blood cells each day

SpaceX's S-1 or 'prospectus' revealed many previously unknown details about the company, including its unprofitability despite doing $18.7B in revenue in 2025, exactly how many voting shares Elon Musk will have in the company (roughly 85%), and more.

About 2,000 US babies are born annually without some portion of their limbs, potentially leading to a lifetime of pricey prosthetics.

Hookworm infection, though risky, may help fight certain autoimmune conditions by tamping down the immune system's inflammatory response.

Studies suggest when you sleep is as important as how much you get, and syncing with your circadian rhythms may lead to less fatigue and improved long-term health outcomes

How fusion—which releases energy when two lighter atoms combine to form a heavier atom—differs from fission

The distributor behind 'Rocky Horror' pulled the film from its scheduled national release, believing it would be a failure, though it eventually amassed a dedicated fanbase through midnight showings, a trend that continues over 50 years later.

During the French Revolution, a botanist's letter asking about "dear Rhus" (poison ivy) was intercepted, leading authorities to suspect he was conspiring with the Russians.

Alzheimer's can lead to brain shrinkage, with an average of around 2% of volume reduction per year

While the first exchange-traded fund (a 'basket' of different assets that can be bought and sold on a stock exchange) in the US only launched in 1993, the global ETF market has grown to more than $10T in the short time since.

In 2026, Finland was named the world's happiest country for the ninth consecutive year based on its wealth, social safety network, and high life expectancy, among other factors.

In 1939, baseball star Lou Gehrig delivered his inspirational 'Luckiest Man' speech after retiring due to the health condition that now bears his name.

The most expensive ad of all time was for Chanel No. 5 perfume and cost roughly $33M to produce in 2004—about $57M in today's dollars.

Despite being favored by 87% of Americans, Congress does not have term limits.